A BetterLife Pharma

BetterLife is an emerging biotech company focused on developing & commercializing patient-friendly compounds to treat mental health issues $BETR

BETR | BETRF

[A BetterLife Pharma @BetterLifeBio]

The most painful condition you've never heard of.

Cluster headache affects 1 in 1,000 people. Many still have
no reliable treatment.

BetterLife Pharma is developing an investigational compound
targeting the root cause — not just the pain.

#clusterheadache #suicideheadache

[A BetterLife Pharma @BetterLifeBio]

Most psychedelics carry a hidden risk - 5-HT2B agonism - 5-HT2B activation is a known liability for LSD, psilocybin, DMT and many non-hallucinogenic analogs.
BETR-001 is a 5-HT2B antagonist - zero agonism. Full cardiac safety package completed in IND studies.

[A BetterLife Pharma @BetterLifeBio]

BETR-001 doesn’t just fix one problem - it hits the receptors involved in many of the conditions. Animal models of depression-anxiety: highly effective. Previous version already showed near-cure results in cluster "suicide" headache patients (Karst 2010).

[A BetterLife Pharma @BetterLifeBio]

BETR-001 changes everything. Previous version already safe in humans. New data proves it’s a powerful inducer of both short- and long-term neuroplasticity - without any psychedelic effects.

[A BetterLife Pharma @BetterLifeBio]

Psychedelics work because they drive new neuronal growth & connections. That’s why they help depression, anxiety, PTSD, addiction & pain. But the hallucinations have always been considered baggage.

[A BetterLife Pharma @BetterLifeBio]

The future of brain repair is here - and it doesn’t make you hallucinate.
BetterLife has unlocked BETR-001 - a patented LSD derivative that is a potent neuroplastogen with ZERO hallucinations.

[A BetterLife Pharma @BetterLifeBio]

BB's Stock Haven : $BETRF 🧠BetterLife Pharma: Revol... https://t.co/J8QN9Q4IRt via @Investors_Hub

[A BetterLife Pharma @BetterLifeBio]

BetterLife Pharma achieves a significant milestone on its way to clinical trials! The US Patent and Trademark Office grants composition of matter for BETR-001 and its related derivatives. More can be read here - https://t.co/Iss7PTuaJt

#PTSD #depression #anxiety #neuropathicpain

[A BetterLife Pharma @BetterLifeBio]

BetterLife Pharma Provides Scientific Update on Neuroplastogenic Activity of BETR-001 https://t.co/BNChRaJ8a0

[A BetterLife Pharma @BetterLifeBio]

BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders https://t.co/JADXMi8Mh1

[A BetterLife Pharma @BetterLifeBio]

BetterLife Announces Debt Settlements https://t.co/NXv4aFA8s6

[A BetterLife Pharma @BetterLifeBio]

BetterLife Pharma Appoints Corporate Advisor https://t.co/Ok9kaLMZ9y

[A BetterLife Pharma @BetterLifeBio]

BetterLife Pharma Appoints New Director https://t.co/etRABEExi9

[A BetterLife Pharma @BetterLifeBio]

💊 Drug Development
In drug discovery, a wide range of pathways are pervasive. But the overriding consistency with all approaches is the hunger, drive, and need to address complexities & challenges of diseases. So, therapies and medicines need to offer tailored made solutions.

[A BetterLife Pharma @BetterLifeBio]

💊 Orphan Drug Designation
Unlike regulatory hurdles, the orphan drug designation was enacted to tackle economic challenges faced by biotech working on rare diseases. The approach is centered on giving financial incentives to biopharma so they can bring a drug to the market.

[A BetterLife Pharma @BetterLifeBio]

💊 FDA’s accelerated approval pathway is a change agent. It can alleviate serious & life-threatening strains on society. However, a pathway concern is that it doesn't require a drug to demonstrate clinical benefit before being approved. Change is needed! https://t.co/tY9FAWzjXz

[A BetterLife Pharma @BetterLifeBio]

💊 Accelerated Approval Designation
An accelerated approval pathway tackles serious & life-threatening conditions. So, it's important for trials to be timely, safeguarded, & transparent. 2025, FDA indicates access to meaningful drugs is vital for patients with high unmet needs.

[A BetterLife Pharma @BetterLifeBio]

🌟Year of #Neuroscience?
J&J off to a flying 2025 with $14.6B buy of Intra-Cellular Therapies. It's clear @JNJNews is beefing up its best-in-class neurological disorder treatments. A complement to its psychiatric disorder drug @Spravato_center. What else is in store in 2025?

[A BetterLife Pharma @BetterLifeBio]

💊 Fast Track Designation
The @FDA approved 50 novel drugs in 2024 and @drughunter_com said 14% went through the ‘accelerated approval pathway’. Total number of novel drugs approved fell 10% 2023-2024. Shockingly 44% were granted Fast Track Designation.
$BETR: CSE
$BETRF: OTCQB

[A BetterLife Pharma @BetterLifeBio]

💊 Fast Track Designation
The Biotech landscape is froth with the need for speed! The key for the FDA is balance patient safety, medicinal sustainability, & corporate suitability. Real aims are meeting serious conditions and high unmet needs.

$BETR: CSE
$BETRF: OTCQB